Crescita Therapeutics Inc
- LAST PRICE0.5700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5500/ 20
- Ask / Lots0.6000/ 5
- Open / Previous Close--- / 0.5700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 6, 2024
Crescita Reports Third Quarter 2024 Results, from 7:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:30AM ET on Wednesday Nov 06, 2024 by Dow JonesPress Release: Crescita Reports Third Quarter 2024 Results, from 7:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crescita Therapeutics Inc | 10.9M | -4.0x | --- |
Nextleaf Solutions Ltd | 11.4M | -14.0x | --- |
Preveceutical Medical Inc | 10.8M | -8.5x | --- |
Voyageur Pharmaceuticals Ltd | 9.8M | -6.3x | --- |
Kane Biotech Inc | 13.8M | -2.5x | --- |
Mojave Brands Inc | 7.0M | -5.6x | --- |
Company Information
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.
Contact Information
- Headquarters
- 2805, Place Louis R RenaudLAVAL, QC, Canada H7V 0A3
- Phone
- 450-680-4722
- Fax
- 905-673-3614
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.9M |
|---|---|
Revenue (TTM) | $17.4M |
Shares Outstanding | 19.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.72 |
EPS | $-0.14 |
Book Value | $0.94 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
